458 related articles for article (PubMed ID: 18484198)
1. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
5. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Untch M; Möbus V; Kuhn W; Muck BR; Thomssen C; Bauerfeind I; Harbeck N; Werner C; Lebeau A; Schneeweiss A; Kahlert S; von Koch F; Petry KU; Wallwiener D; Kreienberg R; Albert US; Lück HJ; Hinke A; Jänicke F; Konecny GE
J Clin Oncol; 2009 Jun; 27(18):2938-45. PubMed ID: 19364964
[TBL] [Abstract][Full Text] [Related]
6. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer.
Tanis E; van de Velde CJ; Bartelink H; van de Vijver MJ; Putter H; van der Hage JA
Eur J Cancer; 2012 Aug; 48(12):1751-6. PubMed ID: 22446021
[TBL] [Abstract][Full Text] [Related]
7. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
[TBL] [Abstract][Full Text] [Related]
8. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
[TBL] [Abstract][Full Text] [Related]
9. Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy.
Dinshaw KA; Budrukkar AN; Chinoy RF; Sarin R; Badwe R; Hawaldar R; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1132-41. PubMed ID: 15978744
[TBL] [Abstract][Full Text] [Related]
10. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
11. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
12. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
Toledano A; Azria D; Garaud P; Fourquet A; Serin D; Bosset JF; Miny-Buffet J; Favre A; Le Floch O; Calais G
J Clin Oncol; 2007 Feb; 25(4):405-10. PubMed ID: 17264336
[TBL] [Abstract][Full Text] [Related]
14. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
[TBL] [Abstract][Full Text] [Related]
15. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
[TBL] [Abstract][Full Text] [Related]
17. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma.
van der Sangen MJ; van de Poll-Franse LV; Roumen RM; Rutten HJ; Coebergh JW; Vreugdenhil G; Voogd AC
Eur J Surg Oncol; 2006 Feb; 32(1):34-8. PubMed ID: 16305821
[TBL] [Abstract][Full Text] [Related]
18. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
[TBL] [Abstract][Full Text] [Related]
19. [A prospective multicenter clinical trial of breast conserving therapy for early breast cancer in China].
Zhang BN; Shao ZM; Qiao XM; Li B; Jiang J; Yang MT; Wang S; Song ST; Zhang B; Yang HJ
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):680-4. PubMed ID: 16438891
[TBL] [Abstract][Full Text] [Related]
20. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
Colleoni M; Zahrieh D; Gelber RD; Holmberg SB; Mattsson JE; Rudenstam CM; Lindtner J; Erzen D; Snyder R; Collins J; Fey MF; Thürlimann B; Crivellari D; Murray E; Mendiola C; Pagani O; Castiglione-Gertsch M; Coates AS; Price K; Goldhirsch A
J Clin Oncol; 2005 Mar; 23(7):1390-400. PubMed ID: 15735115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
